The ETF industry in the U.S. surpassed $5 trillion in assets under management last week, a new record.
Archiv für den Monat: November 2020
Top Goldman dealmaker Lemkau is leaving the bank to helm $15 billion investment firm linked to Dell fortune
Gregg Lemkau, known as one of the top mergers bankers on Wall Street, has advised on hundreds of transactions since joining the bank in 1992.
UK electric vehicle maker Arrival is going public via SPAC at a $5.4 billion valuation
The company competes with Amazon-backed start-up Rivian in the electric van space.
Stocks making the biggest moves in the premarket: Target, Lowe’s, Apple, Boeing, Pfizer & more
The stocks making the biggest moves in premarket trading include Target, Lowe’s, Apple, Boeing, Pfizer, and more.
Bitcoin shoots past $18,000 for the first time since December 2017
Bitcoin is now creeping up toward the all-time high it posted in a late 2017 rally that saw the values of several cryptocurrencies surge.
Ant Group is still capable of securing the world’s biggest IPO, says Chinese investor
Ant Group is still capable of clinching the world’s largest IPO, even as Chinese regulation weighs heavy on the tech giant, a leading investor said.
BNP Paribas says 2 things must happen for the yuan to go global
Yuan’s prominence is rising in global reserves and international trade owing to Beijing’s growing economic influence.
Target crushes estimates as retailer uses new shopper habits to gain market share
Target on Wednesday reported fiscal third-quarter earnings that easily outpaced analysts‘ estimates as the discount retailer won market share by turning shoppers‘ pandemic habits into lasting gains.
Lowe’s shares tumble as earnings fall short despite robust sales gains
The results from Lowe’s come one day after Home Depot reported third-quarter earnings that beat estimates.
Another round of vaccine optimism rinse and repeat
But to a lesser degree and perhaps shorter lasting timeframe
Pfizer passed the final hurdle of meeting the safety requirements to apply for emergency-use approval, but the announcement also came with a bit of an attempt to try and one up Moderna as they claim that their vaccine is 95% effective upon final analysis.
Pfizer passed the final hurdle of meeting the safety requirements to apply for emergency-use approval, but the announcement also came with a bit of an attempt to try and one up Moderna as they claim that their vaccine is 95% effective upon final analysis.